Just reported
From Labcorp's results release of 28 octobre 2026; its quarterly report has since been filed.
Actual
3,81B $US
+6,9 % y/y
+2,1 % q/q
Guided
—
No guide given
Actual
3,22 $US
+3,2 % y/y
-12 % q/q
Guided
—
No guide given
Actual
402,1M $US
+1,4 % y/y
-11 % q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Les parts du chiffre d'affaires sont des estimations pour year ended 2025-12-31, pas des chiffres tirés d'un document officiel.
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
Construit à partir des documents déposés par Labcorp Holdings Inc. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
370,57 $US-0,5 %clôture 13 nov.
Chiffres jusqu’au 30 septembre 2026, issus du 10-Q déposé le 30 octobre 2026
Labcorp sells medical testing to doctors, hospitals, health plans and patients, plus drug-development laboratory testing to pharmaceutical and biotechnology companies.
Grade A
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 41 de l’historique des notes de Labcorp Holdings Inc.. Les 39 autres remontent jusqu’à octobre 2016.